Table 2.

CpG sites that show significant difference in methylation status between APOA2 genotypes according to saturated fat intake in 3 populations¹

				CC vs. TT
				Low-SFA			High-SFA
	CpG site	Chr:Position2	n	β (SE)	P value3	n	β (SE)	P value3
BPRHS	cg04436964	1:161,167,745	20	0.031 (0.006)	1.22 × 10−6	20	0.035 (0.005)	4.35 × 10−8*
	cg24429974	1:161,195,180	20	0.010 (0.006)	3.77 × 10−3	20	0.009 (0.008)	0.255
	cg24847046	1:161,135,079	20	−0.009 (0.006)	0.185	20	−0.017 (0.006)	0.011
GOLDN	cg04436964	1:161,167,745	146	0.009 (0.002)	1.59 × 10−3	233	0.013 (0.002)	1.02 × 10−10*
	cg24429974	1:161,195,180	146	0.009 (0.002)	1.51 × 10−4	233	0.011 (0.002)	1.84 × 10−10*
	cg24847046	1:161,135,079	146	−0.004 (0.003)	0.106	233	−0.007 (0.002)	2.51 × 10−4
FHS	cg04436964	1:161,167,745	108	0.031 (0.004)	5.23 × 10−12*	135	0.040 (0.003)	1.21 × 10−25*
	cg24429974	1:161,195,180	108	0.022 (0.003)	1.63 × 10−10*	135	0.021 (0.003)	3.33 × 10−12*
	cg24847046	1:161,135,079	108	−0.013 (0.003)	3.38 × 10−6	135	−0.018 (0.003)	2.70 × 10−8*

¹*P value ≤1.1 × 10⁻⁷. APOA2, apolipoprotein A-II; BPRHS, Boston Puerto Rican Health Study; FHS, Framingham Heart Study; GOLDN, Genetics of Lipid Lowering Drugs and Diet Network.

²The physical position of CpG sites was based on the genome build 37.

³The threshold of epigenome-wide significance is P value ≤1.1 × 10⁻⁷.